Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
August 31 marks 25 years of International Overdose Awareness Day with theme '25 Years On. Still Needed' as CDC reports third consecutive year of declining overdose deaths.
Middlesex-London Health Unit data shows opioid deaths fell to 62 in 2025 from 72 in 2024, marking three years of progress while officials warn gains remain fragile.
Vanderbilt Health opens enrollment for the TAB study, a randomized trial testing whether the GLP-1 medication tirzepatide can help stabilize patients on buprenorphine and prevent relapse.
Annual report shows 634 homeless New Yorkers died in 2025, down from 770 in 2024, marking the first decrease in seven years amid expanded harm reduction efforts.
A real-world study of Oregon's regulated psilocybin program demonstrates encouraging outcomes for depression and anxiety, offering valuable data as FDA considers approval for psychedelic therapy.
University of Tennessee audit uncovers serious problems in Dr. Craig Towers' influential study promoting detox for pregnant women with opioid addiction, raising ethical concerns about patient consent.
Santa Cruz County reports 20 overdose deaths in first half of 2026, down from 36 in 2025, marking third straight year of decline after peak of 130+ deaths in 2023.
SAMHSA's April 2026 guidance restricts federal grant funds for syringe services programs, removing support for fentanyl test strips and overdose hotlines while preserving naloxone funding.
Suzetrigine (Journavx) becomes the first novel non-opioid pain medication approved by FDA in over 20 years, offering surgery patients effective pain relief with significantly lower opioid use.